Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

BACKGROUND: Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed. METHODS: We investigated the role of melanoma-associated antibodies as predicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Fässler, Mirjam, Diem, Stefan, Mangana, Joanna, Hasan Ali, Omar, Berner, Fiamma, Bomze, David, Ring, Sandra, Niederer, Rebekka, del Carmen Gil Cruz, Cristina, Pérez Shibayama, Christian Ivan, Krolik, Michal, Siano, Marco, Joerger, Markus, Recher, Mike, Risch, Lorenz, Güsewell, Sabine, Risch, Martin, Speiser, Daniel E., Ludewig, Burkhard, Levesque, Mitchell P., Dummer, Reinhard, Flatz, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383238/
https://www.ncbi.nlm.nih.gov/pubmed/30786924
http://dx.doi.org/10.1186/s40425-019-0523-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383238/
https://www.ncbi.nlm.nih.gov/pubmed/30786924
http://dx.doi.org/10.1186/s40425-019-0523-2

Ejemplares similares